Treslin Inhibitors
Chemical inhibitors of Treslin target various signaling pathways and kinases that are essential for its activation and function in the initiation of DNA replication. ATR inhibitors such as VE-821 and AZ20 can inhibit Treslin by blocking the ATR-CHK1 signaling pathway, which is crucial for the activation of Treslin, especially in the control of the G1/S phase transition. Similarly, the ATM inhibitor KU-60019 and CP-466722 disrupt the ATM-CHK2 pathway, which is also involved in the activation and function of Treslin, specifically in response to DNA damage. These inhibitors collectively function to impede the necessary kinase signaling that Treslin relies on for its activation and subsequent promotion of DNA replication initiation.
Furthermore, CHK1 inhibitors like SCH900776, PF-00477736, and LY2603618 directly inhibit the CHK1 kinase, which is required for the phosphorylation and subsequent activation of Treslin. Inhibition of CHK1 thereby leads to a decrease in Treslin function. In a similar fashion, CDK inhibitors including Dinaciclib and Flavopiridol restrict the phosphorylation of Treslin by inhibiting CDKs, which are necessary for its activation. WEE1 inhibitors, such as MK-1775 and PD0166285, indirectly suppress Treslin by reducing CDK activity through the inhibition of WEE1 kinase, which is a regulator of CDKs.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
Treslin functions in the initiation of DNA replication in concert with ATR-CHK1 signaling. VE-821 is an ATR inhibitor that would inhibit Treslin by preventing activation of the ATR-CHK1 pathway, which is crucial for Treslin's role in the control of the G1/S phase transition. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Treslin activity is dependent on phosphorylation by CDK, thus inhibition of CDKs by Dinaciclib can lead to a functional inhibition of Treslin by preventing its necessary phosphorylation. | ||||||
KU 60019 | 925701-46-8 | sc-363284 sc-363284A | 10 mg 50 mg | $243.00 $1015.00 | 1 | |
Treslin interacts with the ATM-CHK2 pathway, which is involved in DNA damage response. Inhibiting ATM with KU-60019 would disrupt this pathway, indirectly inhibiting Treslin function required for DNA replication. | ||||||
AZ20 | 1233339-22-4 | sc-503186 | 5 mg | $250.00 | 1 | |
Similar to VE-821, AZ20 inhibits ATR and would suppress the ATR-CHK1 pathway activation, upon which Treslin relies for its function in DNA replication initiation. | ||||||
PF 477736 | 952021-60-2 | sc-362781 sc-362781A | 5 mg 25 mg | $113.00 $423.00 | ||
PF-00477736 is a CHK1 inhibitor that would disrupt the CHK1 signaling required for the activation of Treslin, thus functionally inhibiting Treslin's role in DNA replication. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits CDKs necessary for the phosphorylation and activation of Treslin, leading to its functional inhibition with respect to DNA replication initiation. | ||||||
ETP-46464 | 1345675-02-6 | sc-497432 | 10 mg | $550.00 | ||
ETP-46464 is another ATR inhibitor that would prevent the ATR-CHK1 signaling required for Treslin activation, thus functionally inhibiting Treslin. | ||||||
LY2603618 | 911222-45-2 | sc-364526 sc-364526A | 5 mg 50 mg | $214.00 $1809.00 | ||
LY2603618 would inhibit CHK1, a kinase that Treslin needs to be activated by in order to function properly during DNA replication, thereby inhibiting Treslin activity. | ||||||